No Data
Hong Kong stocks movement | Aime vaccine (06660) rose over 7%, mRNA shingles vaccine has recently applied for clinical trials.
Aimee Vaccine (06660) rose over 7%, as of the time of writing, up 7.09%, priced at 5.89 Hong Kong dollars, with a trading volume of 27.0458 million Hong Kong dollars.
Deepseek ignites the re-evaluation of asset values in China. What kind of companies are urgently in need of re-evaluation?
Since the beginning of this year, foreign Institutions such as Goldman Sachs, Deutsche Bank, and UBS Group have continuously been optimistic about China Assets. Especially recently, with the popularity of Deepseek and "Nezha 2," this optimism has become even more pronounced. Recently, a Research Report from Deutsche Bank has been particularly aggressive, stating that 2025 will be a year for Global investors to reassess the Chinese market. It is expected that the "valuation discount" of China Stocks will disappear, and the bull market in A-shares and Hong Kong stocks is likely to continue and surpass previous highs. The report suggests that investors pay attention to leading companies in China's AI and high-end service industries, believing these areas have great potential.
Gelonghui Selected Announcement (Hong Kong Stocks) | Semiconductor Manufacturing International Corporation (00981.HK) expects sales revenue to exceed 8 billion dollars in 2024, a year-on-year growth of 27%.
【Today's Focus】Semiconductor Manufacturing International Corporation (00981.HK) expects sales revenue to exceed 8 billion USD in 2024, a 27% year-on-year increase. Semiconductor Manufacturing International Corporation (00981.HK) announced its unaudited results for the three months ending December 31, 2024. In the fourth quarter of 2024, sales revenue was 2.2073 billion USD, a quarter-on-quarter increase of 1.7% and a year-on-year increase of 31.5%; gross profit was 0.499 billion USD, a quarter-on-quarter increase of 12.3% and a year-on-year increase of 81.5%; the gross margin for the fourth quarter of 2024 was 22.6%, compared to 20.5% in the third quarter of 2024 and the fourth quarter of 2023.
AIM Vaccine Advances MRNA Shingles Vaccine to Clinical Trials, Eyeing Global Market
Aimee Vaccine (06660.HK): The mRNA shingles vaccine has been submitted for clinical trials, with T cell immunity, IgG antibody titers, and membrane antigen fluorescent antibody titers significantly higher than those of commercially available recombinant s
On February 11, Gelonghui reported that Aimee Vaccine (06660.HK) announced that the group is actively promoting the development of its vaccine product pipeline according to its established Global Strategy. Utilizing the advantages of the mRNA technology platform, through continuous technological innovation, the research and development of the mRNA vaccine series products is progressing rapidly. The mRNA shingles vaccine has recently been submitted for clinical review to the Center for Drug Evaluation (CDE) of China's Pharmaceutical Administration. In the preclinical animal trials, results from third-party testing agencies showed that the group's mRNA shingles vaccine elicited specific T cell immunity, specific IgG antibody titers, and fluorescent antibodies against membrane antigens (FAMA).
AIM Submits Clinical Trial Application to US FDA for MRNA RSV Vaccine
AIM Vaccine Insider Ups Holding By 649% During Year
